Biotech

All Articles

AN 2 halves head count, quits stage 3 test after records let down

.AN2 Therapies is actually reassessing its service in reaction to poor midphase information, promisi...

Merck pays $700M for bispecific, spying autoimmune opening and also opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying out $700 million upfront to test Amgen in a blood cancer market. ...

Gilead pays J&ampJ $320M to go out licensing offer for seladelpar

.With Gilead Sciences on the verge of an FDA decision for its liver disease drug seladelpar, the pro...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks may observe the providers putting together tents at basecamp behind Eli Lilly in an...

Entero giving up workers, vacating office as well as stopping R&ampD

.Mattress Liquidators has actually turned Entero Therapeutics white as a sheet. The lender ordered E...

Exelixis loses ADC after deciding it's no suit for Tivdak

.Exelixis is giving up on its cells variable (TF)- targeting antibody-drug conjugate after concludin...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.3 full weeks after Roche's Genentech device bowed out an SHP2 prevention contract, Relay Therapeuti...

Stoke's Dravet syndrome med launched of partial medical grip

.Stoke Rehabs' Dravet syndrome medication has actually been freed from a predisposed hold, removing ...

Fierce Biotech's Gabrielle Masson provides Ferocious 15 at NYSE

.Strong Biotech Associate Editor Gabrielle Masson offered the 2024 course of Tough 15 victors on the...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has axed its once-monthly twin GLP-1/ GIP receptor agonist, finishing (PDF) advancemen...